Important ISIS Pharma Data Coming at AHA Meeting – November 16-20, 2013 Print E-mail
By Brian Wilson - Lead Contributor   
Friday, 15 November 2013 10:16
A number of pharmaceutical companies developing products for cardiovascular indications will be presenting clinical trial data at the upcoming American Heart Association (AHA) Scientific Sessions 2013 convention in Dallas, Texas at the Dallas Convention Center.
Read more...
 
Are Aeltiq Aesthetics and Solta Medical In Play? Print E-mail
By Scott Matusow   
Thursday, 14 November 2013 14:12
At stockmatusow.com, we frequently track and trade companies we feel are ripe to be acquired. If the due diligence is done correctly, trading these can be very rewarding.
Read more...
 
Will Sarepta Find a Floor? Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 14 November 2013 10:27
For those who weren’t aware, it Sarepta Therapeutics ($SRPT) recently received feedback from the FDA that implied in its commentary that the company’s chances for early approval were shot, and that the Phase IIb data that seemed to assure investors of approval for the Duchenne Muscular Dystrophy drug eteplirsen was questionable.
Read more...
 
Q&A with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals Print E-mail
By BioMedReports.Com   
Thursday, 14 November 2013 09:59
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is a specialty pharmaceutical company developing novel medications for central pain disorders, including fibromyalgia (FM) and post-traumatic stress disorder (PTSD).
Read more...
 
Keryx: Cut Through The Noise and Get To The Substance Print E-mail
By Staff and Wire Reports   
Wednesday, 13 November 2013 00:00
icon_newsnotesTwitter can be a great source of information for an ever-increasing number of investors. But as with most technological inventions, it can be misused.
Read more...
 
An Overview of Horizon Pharma After Q3 Earnings Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 12 November 2013 10:04
Recently, Horizon Pharma (HZNP) has been quite an interesting play in the biotech space. Speculation on the bullish side has been dominating (as demonstrated with the 95% rally the stock saw in the last three months), although bearish pressure seems to keep the $5 ceiling on the stock intact.
Read more...
 
Solta Medical Hires Investment Banker, Merger-Acquisition Imminent Print E-mail
By Scott Matusow   
Tuesday, 12 November 2013 00:50
In the on-going saga of Solta Medical (SLTM), the next chapter has been written, when on the company's earning's call yesterday, it announced it has hired Piper Jaffray as its financial advisor/investment banker to explore strategic alternatives.
Read more...
 
Ohr Pharma: A Pure 2014 Catalyst Play With Large Potential Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 11 November 2013 08:43
One of the biotechs of 2013 that continues to hold its ground is Ohr Pharmaceutical (NASDAQ: OHRP) – a company that is best known for its Squalamine eye drops which are being developed as a treatment for wet age-related macular degeneration (wet AMD).
Read more...
 
Decision Diagnostics On Track For Growth and Increased Revenues Print E-mail
By Staff and Wire Reports   
Thursday, 07 November 2013 09:18
icon_closerlookThe Shasta GenStrip blood glucose monitoring test strip for in-home use received FDA approval on November 30, 2013.  Decision Diagnostics Corp. (OTCBB: DECN) has been fighting a battle to bring the Shasta GenStrip to market ever since and DECN’s management is now realizing the fruits of their labor.  
Read more...
 
Why Shares of Zalicus May Be Ready To Make A Move Print E-mail
By Michael Morhamus, Contributor   
Wednesday, 06 November 2013 06:21
icon_MarketCatalystIn case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a potentially huge binary event from Zalicus, Inc. (NASDAQ:ZLCS);
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 18 of 56

Newsletter